Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2012        Go!    
 
 
January 16, Tuesday 2018 3:13 PM       

       HEADLINES: DYFI activist hacked in Thiruvananthapuram                                              Gita Gopinath’s economic advices must be carefully approached: CPI                                              Udayamperoor Neethu murder case: Accused found hanging                                              ‘Joker’ like Uzhavoor is not needed for NCP: Mani C Kappan                                              Vigilance registers FIR against Thomas Chandy                                              SC judge in Loya case breaks down during meeting with CJI                                              SC crisis seems unresolved, will take couple days to settle: AG                                              CJI sets new five-Judge constitution bench, sans four SC judges                                              Couple arrested after 13 brothers and sisters held captive                                              Palestinian leaders vote to suspend recognition of Israel                                              Pak provides safe sanctuaries to terrorists: MQM                                              Centurion Test: Rain halts play on third day                                              Khelo India's official anthem released                                              Kaumudi Facebook
       SCI&TECH Next Article: Clearing the myths about osteoporosis  
       Aspirin a day may keep liver cancer away
 
         Posted on :18:27:33 Oct 21, 2017
   
A A
       Last edited on:18:27:33 Oct 21, 2017
         Tags: Aspirin a day may keep liver cancer away
 

WASHINGTON DC: Taking aspirin daily can reduce the risk of liver cancer, a new study suggested.

The researchers found that everyday aspirin therapy could significantly associate with a reduced risk in hepatitis B related liver cancer.

Hepatitis B is a viral infection that attacks the liver. HBV can be contracted through contact with an infected person's blood or other bodily fluid, and the infection can either be acute or chronic.

It has been estimated that around estimated 240 million people worldwide have chronic HBV. The findings also show Africa and Asia as the highest prevalence of the virus.

Previous studies also show that daily aspirin therapy -- which is often prescribed to prevent cardiovascular disease -- may also prevent the development of cancer.

However, on another note clinical evidence is being lacked for the effectiveness of aspirin therapy in preventing HBV-related liver cancer.

Researcher Teng-Yu Lee from the Taichung Veterans General Hospital conducted a nationwide cohort study to determine if aspirin therapy could, indeed, reduce liver cancer risk.

"Liver cancer is the second leading cause of cancer death worldwide, and HBV is the most prevalent risk factor in our region," said Dr. Lee who's the lead author of the study.

"HBV-related liver cancer is therefore a major public health issue with a severe socioeconomic impact," he stated.

Dr. Lee stated that therapies which reduce the risk of liver cancer like, nucleos(t)ide analogue therapy, do not completely eliminate the risk. Adding, he also mentioned that most HBV carriers are not indicated for antiviral therapy, so another effective way of reducing liver cancer risk needs to be developed.

"Aspirin has been investigated to explore its chemopreventive effect in cancers that are related to chronic inflammation, particularly in the prevention of colorectal cancer. However, clinical evidence supporting the chemopreventive effect of aspirin therapy on liver cancer remains limited. Therefore, we conducted a large-scale cohort study to evaluate the association of aspirin therapy with HBV-related liver cancer," he noted.

Retrieving past medical records for the study, they screened records of 204,507 patients with chronic hepatitis B, and excluded patients with other forms of infectious hepatitis, from the National Health Insurance Research Database between the year 1998 and 2012.

The past findings showed that 1,553 patients who continuously received daily aspirin for at least 90 days were randomly matched 1:4 with 6,212 patients who had never received anti- platelet therapy by means of propensity scores consisting of baseline characteristics.

The researchers analyzed both cumulative incidents of and hazard ratios for HCC development after adjusting for competing mortality.

Cumulative incidence of liver cancer in the group treated with aspirin therapy was significantly lower than that in the untreated group in five years.

The researchers in their multivariate regression analysis found that aspirin therapy was independently associated with reduced liver cancer risk.

"For effectively preventing HBV-related liver cancer, the findings of this study may help hepatologists treat patients with chronic HBV infection in the future, particularly for those who are not indicated for antiviral therapy. We are pursuing prospective investigations for further confirming the findings," stated Dr. Lee.

The study presented at The Liver Meeting held by the American Association for the Study of Liver Diseases (AASLD).

A A
       SCI&TECH
Next Article: Clearing the myths about osteoporosis
 
 
SCI&TECH HEADLINES
Soon, you can demote group admins on WhatsApp  
Regular yoga can slow down ageing of brain: Study  
What are haemorrhoids (piles) and what causes them?  
WhatsApp facilitates quick switch from voice to video call  
The Thin and Light Lenovo Ideapad 720s shines at Digit Zero 1 Awards  
Frequent heartburns up cancer risk in older adults  
Blueberry vinegar can help fight dementia  
iPhones with older batteries will take a hit in performance: Apple  
Eighth planet found in faraway solar system, matching ours  
Google brings a host of new features on Pixel 2  
Scientists turn beer into suitable petrol  
Space gives a sense of humbleness: NASA astronaut  
Researchers discover genes to prolong human life  
Google announces best apps of 2017  
This technology can help to reduce accidents on icy roads  
Yepzon launches in India; promises smart safety solutions  
Soon, you'll be able to control diabetes with your phone  
Turning bacteria into 'world's smallest tape recorders'  
How breastmilk protects babies from food allergy decoded  
Stars among the oldest in our galaxy discovered  
Apple delays release of smart speaker - HomePod  
Owning a dog may add years to your life  
'Textisms' actually add meaning to written words  
Sugar may heal wounds, says study  
Heart-stopping sex? It's rare  
 
Do you think Sreejith issue will get politicised if he continues strike, despite CM's assurance for action?
yes
 
no
 
no opinion
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy